Merck & Co. has received FDA approval for Keytruda Qlex, the first subcutaneous (SC) administered immune checkpoint inhibitor that can be injected in approximately one minute, a significant improvement over the traditional 30-minute intravenous infusion. Based on clinical trials demonstrating comparable efficacy and safety to the original formulation, Keytruda Qlex offers enhanced patient convenience and healthcare delivery efficiency in treating solid tumors. This innovation builds on Keytruda’s blockbuster status, with 2024 sales topping $29 billion.